logo

For the Inventor, By the Inventor

Laguna Hills, CA, United States of America

Gary C Lee

This inventor holds 21 USPTO granted patents, primarily in Furanone Chemistry. Top assignee: Allergan, Inc.. Active years: 1990-1994.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gary C Lee. Retrieved from https://idiyas.com/inventor/gary-c-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 100.0

Average Co-Inventor Count = 1.2

ph-index = 6

Forward Citations = 161(Granted Patents)


Location History:

  • Laguna Hille, CA (US) (1992)
  • Laguna Hills, CA (US) (1990 - 1994)

Company Filing History:

goldMedal21 out of 2,287 
 
Allergan, Inc.
 patents

Years Active: 1990-1994

Loading Chart...
Areas of Expertise:
Anti-Inflammatory Furanones
5-Hydroxy-2(5H)-Furanones
4-Substituted 2-5(H)-Furanones
Calcium Channel Modulators
Synthesis Processes
Trialkylsilyl Compounds
Dihydroxy Compounds
Alkyl Substituents
Phenyl Substituents
Furaldehydes
Alkanedioates
21 patents (USPTO):Explore Patents
1. 5376676 - Process of using anti-inflammatory furanones as selective calcium (1994-12-27),
2. 5322953 - 2-trialkylsilyl-3-furaldehydes (1994-06-21),
3. 5298633 - Intermediates and processes for preparing 4-substituted 2-5(H)-furanones (1994-03-29),
4. 5225571 - Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as (1993-07-06),
5. 5212172 - 4-(1-hydroxy-2-substituted amino)ethyl-5-hydroxy-2(5H)-furanones as (1993-05-18),
6. 5183906 - 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or (1993-02-02),
7. 5171864 - Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega alkane-dioates and (1992-12-15),
8. 5171863 - Intermediates for preparing 4-substituted 2-5(H)-furanones as (1992-12-15),
9. 5169963 - Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates (1992-12-08),
10. 5134128 - Anti-inflammatory furanones (1992-07-28),
11. 5089485 - Anti-inflammatory furanones (1992-02-18),
12. 5082954 - Intermediates and processes for preparing 4-substituted 2-5(H)-furanones (1992-01-21),
13. 5081261 - 4-(1-hydroxy-2-N-substituted sulfonamido) (1992-01-14),
14. 5081147 - 4-(1-hydroxy-2-substituted amino)ethyl-5-hydroxy-2(5H)-furanones as (1992-01-14),
15. 5059611 - Anti-inflammatory 5-hydroxy-2-furanones (1991-10-22),

Title: Innovations and Contributions of Gary C. Lee

Introduction

Gary C. Lee, a prominent innovator based in Laguna Hills, California, has made significant contributions to the field of pharmaceuticals with a portfolio of 21 patents to his name. His work focuses on the development of anti-inflammatory compounds, which hold potential for treating a wide array of health conditions.

Latest Patents

Among his latest innovations are patents related to the process of using anti-inflammatory furanones as selective calcium channel inhibitors. These compounds, specifically the 4-(C.sub.10 -C.sub.20)alkyl-2(5H)-furanone, offer therapeutic effects for various conditions such as hypertension, angina, cardiac arrhythmia, pulmonary hypertension, aortic insufficiency, Raynaud's disease, migraine headaches, and more. Furthermore, his research on 2-trialkylsilyl-3-furaldehydes explores the production of anti-inflammatory 4-substituted 2-furanones, utilizing intermediates that can significantly advance treatment options for diverse medical issues.

Career Highlights

Gary C. Lee's pioneering efforts have made substantial impacts in the pharmaceutical industry, especially through his work at Allergan, Inc. His expertise in drug development and innovation has been a driving force behind some of the latest advancements in anti-inflammatory therapies.

Collaborations

Throughout his career, Gary has collaborated with notable peers, including Michael E. Garst and John N. Bonfiglio. These partnerships have contributed to the research and development of groundbreaking therapies that address significant health challenges.

Conclusion

Gary C. Lee stands out as a key figure in pharmaceutical innovation, exemplifying dedication to discovering effective treatments for various diseases. His patents and collaborative efforts highlight the importance of innovation in improving healthcare outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…